Rapt Therapeutics $RAPT Stock Position Lessened by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. trimmed its holdings in Rapt Therapeutics (NASDAQ:RAPT) by 21.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 344,237 shares of the company’s stock after selling 95,939 shares during the quarter. Rapt Therapeutics makes up about 1.8% of Fcpm Iii Services B.V.’s holdings, making the stock its 8th biggest position. Fcpm Iii Services B.V. owned 1.24% of Rapt Therapeutics worth $8,878,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of RAPT. Invesco Ltd. boosted its stake in Rapt Therapeutics by 411.7% during the 1st quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock worth $72,000 after purchasing an additional 47,391 shares during the period. AQR Capital Management LLC acquired a new position in Rapt Therapeutics in the first quarter valued at $188,000. Dimensional Fund Advisors LP purchased a new stake in shares of Rapt Therapeutics in the third quarter valued at about $231,000. UBS Group AG raised its holdings in shares of Rapt Therapeutics by 680.3% in the third quarter. UBS Group AG now owns 28,808 shares of the company’s stock valued at $743,000 after buying an additional 25,116 shares during the last quarter. Finally, Bridgeway Capital Management LLC boosted its stake in shares of Rapt Therapeutics by 32.0% during the third quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock worth $532,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Lifesci Capital lowered Rapt Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, January 20th. Clear Str downgraded Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. HC Wainwright cut Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price objective for the company. in a research report on Tuesday, January 20th. Barclays downgraded Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 target price on the stock. in a research note on Wednesday, January 21st. Finally, TD Cowen cut Rapt Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $48.44.

Rapt Therapeutics Price Performance

Shares of Rapt Therapeutics stock opened at $58.02 on Monday. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. Rapt Therapeutics has a 52-week low of $5.67 and a 52-week high of $58.02. The company’s 50-day simple moving average is $52.37 and its 200-day simple moving average is $36.33.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.